Insights On Drug Development

  1. Small Molecule Orphan Drugs: Status Quo, Challenges, And Perspectives 3/11/2026

    By establishing robust manufacturing processes and scalable production strategies from the outset, developers can help de-risk orphan drug production, improve efficiency, and position their programs for greater long-term success.

  2. Asymchem's World-Class TIDES Hub: Scaling Innovations For The Future 3/11/2026

    A tech‑driven, integrated ecosystem strengthens TIDES development and scale‑up, enabling reliable progression from early molecular design to commercial delivery as pipelines grow more complex.

  3. What Sponsors Get Wrong When Selecting A CRO 3/9/2026

    Gene therapy immunogenicity requires platforms, judgment, and regulatory fluency beyond ADA norms. Relying on biologics criteria creates gaps; CGT expertise ensures reliable, interpretable results.

  4. Why Your Bioanalysis Bottleneck Is Costing You More Than You Think 3/9/2026

    This piece explains why turnaround time is a strategic variable, where speed is truly achievable, and how automation reshapes the path from sample submission to decision‑ready data.

  5. Silencing CDMO Project Noise: The Power Of Low-Drama Drug Development 3/3/2026

    Move beyond reactive firefighting by prioritizing disciplined leadership and data-driven milestones. The winning model for complex programs is focused, high-maturity, low-drama execution.

  6. Navigating Nitrosamine Impurities In Pharmaceutical Drug Development 3/3/2026

    Understanding formation mechanisms and potency categorization allows developers to mitigate risks early, ensuring regulatory compliance and patient safety without compromising product performance.

  7. Nasal Delivery: Strategies For Success 3/2/2026

    A strengthened partnership enhances manufacturing for an ultra‑rare disease therapy, leveraging advanced containment upgrades to improve safety, reliability, capacity, and maintain global patient access.

  8. Re-Thinking ASD Development: When Your Molecule Breaks The Rules 2/26/2026

    A solvent‑free, fusion‑based approach streamlines amorphous solid dispersion development, enabling rapid early screening, improved performance, and sustainable manufacturing.

  9. From Molecule To Milestone: Fast Track Formulation 2/26/2026

    Fast‑track, data‑driven formulation strategies align early decisions with long‑term goals, enabling First‑in‑Human progress while reducing risk, avoiding rework, and supporting manufacturable development.

  10. Converting From A Spray-Dried Dispersion To A KinetiSol Formulation In <5 Months 2/26/2026

    A development team quickly turned a low‑bioavailability, high‑burden formulation into a streamlined, clinically improved version, boosting exposure, simplifying manufacturing, and accelerating progress.